Bioventus Inc.

BVS • Medical - Devices

$14.07

▼ -0.29 (-2.02%)

Current price

EarningsLatest report: Jun 27, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$996.70M

Growth

6.1%

Cash Flow

4/5

Trend

Mostly stable

Evidence

Positive free cash flow · 1.07Consistent free cash flow · 4/5Reasonable earnings multiple · 21.81Healthy liquidity · 1.7

Financial data as of: Jun 27, 2026, 12:00 AM UTCLast earnings update: Jun 27, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:13 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$14.07

Change-2.02%

Shares Out70.84M

Market Cap$996.70M

Enterprise Value$985.99M

52W Range6.25 - 15.89

Beta0.65

P/E18.30

P/S1.71

P/B4.37

P/FCF13.22

EV/Sales1.69

Price$14.07

Change-2.02%

Shares Out70.84M

Market Cap$996.70M

Enterprise Value$985.99M

52W Range6.25 - 15.89

Beta0.65

P/E18.30

P/S1.71

P/B4.37

P/FCF13.22

EV/Sales1.69

EV/EBITDA10.42

EV/FCF13.08

Earnings Yield5.46%

FCF Yield7.56%

Dividend Yield0.00%

Gross Margin67.32%

Oper. Margin10.31%

Profit Margin4.00%

Debt/Eq1.69

Current Ratio1.70

Quick Ratio1.19

Revenue 5Y6.13%

Target$18.33

Target Upside30.28%

Target Median$18.00

Target Range18.00 - 19.00

Volume1.52M

Avg Volume641.53K

EPS Surprise0.06

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

46/100

Financial Strength

Debt, cash, stability

55/100

Growth Potential

Revenue and expansion

58/100

Price Attractiveness

Cheap or expensive today

84/100

Why this score▼

Positive free cash flow · 1.07Consistent free cash flow · 4/5Reasonable earnings multiple · 21.81Healthy liquidity · 1.7

Analyst view

Analyst sentiment and price target

BVS

Analyst sentiment

Based on 7 analyst votes · 2026-09-05

86/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$15.00

Mean

$17.00

Median

$18.00

High

$18.00

Company Overview

IPO: 2/11/2021

Industry: Medical - Devices

P/B i: 4.37

Debt / Equity i: 1.69

Operating Margin: 10.31%

Net Margin: 4.00%

ROE i: -

ROIC: -

Financial Health

Score11 / 20

Debt / Equity: 1.69

Current Ratio: 1.70

Quick Ratio: 1.19

Status: Moderate

Insider Transactions

Recent executive and insider activity

Beyer Pat

Transaction: 06/03/2026

BUY

Change

+25,146

Price

Not reported

Filing

06/04/2026

Type

BUY

Cowdy Philip G.

Transaction: 06/03/2026

BUY

Change

+25,146

Price

Not reported

Filing

06/04/2026

Type

BUY

HAWKINS WILLIAM A

Transaction: 06/03/2026

BUY

Change

+30,994

Price

Not reported

Filing

06/04/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Beyer Pat	BUY	+25,146	Not reported	06/03/2026	06/04/2026
Cowdy Philip G.	BUY	+25,146	Not reported	06/03/2026	06/04/2026
HAWKINS WILLIAM A	BUY	+30,994	Not reported	06/03/2026	06/04/2026
Ladone Mary Kay	BUY	+25,146	Not reported	06/03/2026	06/04/2026
McMurry-Heath Michelle	BUY	+25,146	Not reported	06/03/2026	06/04/2026
NEELS GUIDO J	BUY	+25,146	Not reported	06/03/2026	06/04/2026
NOHRA GUY P	BUY	+25,146	Not reported	06/03/2026	06/04/2026
STALNECKER SUSAN M	BUY	+25,146	Not reported	06/03/2026	06/04/2026
SUTTER MARTIN P	BUY	+25,146	Not reported	06/03/2026	06/04/2026
Bartholdson John A.	BUY	+25,146	Not reported	06/03/2026	06/04/2026
Beyer Pat	SELL	-32,282	Not reported	06/02/2026	06/04/2026
Beyer Pat	BUY	+32,282	Not reported	06/02/2026	06/04/2026
Cowdy Philip G.	SELL	-32,282	Not reported	06/02/2026	06/04/2026
Cowdy Philip G.	BUY	+32,282	Not reported	06/02/2026	06/04/2026
HAWKINS WILLIAM A	SELL	-39,789	Not reported	06/02/2026	06/04/2026
HAWKINS WILLIAM A	BUY	+39,789	Not reported	06/02/2026	06/04/2026
Ladone Mary Kay	SELL	-32,282	Not reported	06/02/2026	06/04/2026
Ladone Mary Kay	BUY	+32,282	Not reported	06/02/2026	06/04/2026
McMurry-Heath Michelle	SELL	-32,282	Not reported	06/02/2026	06/04/2026
McMurry-Heath Michelle	BUY	+32,282	Not reported	06/02/2026	06/04/2026

About the Company

Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Source - link

Peers

AVNS BFLY CBLL CTKB KIDS LAB SMLR SRDX TMCI VREX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Seeking Alpha

Bioventus Q2 Earnings Call Highlights

Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

MarketBeat

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-06	0.09	0.15	0.06
2026-03-05	0.22	0.24	0.02
2025-11-04	0.215	0.15	-0.065
2025-08-06	0.22	0.21	-0.01
2025-05-06	0.06	0.08	0.02
2025-03-11	0.08	0.15	0.07
2024-11-05	0.06	0.06	0
2024-08-06	0.07	0.19	0.12
2024-05-07	-0.05	0.07	0.12
2024-03-12	0.06	0.07	0.01
2023-11-07	0.06	0.05	-0.01
2023-08-08	0.03	0.14	0.11